Clinical trials
Leukemia, Myeloid, Acute clinical trials
Below are recruiting leukemia, myeloid, acute clinical trials, each written for real people, not researchers. We’re tracking 619 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06904066RecruitingPhase 1
Custom T cells for blood cancers with specific mutations
This trial tests a personalized treatment where your immune cells are collected, modified to recognize unique cancer markers (neoantigens) from TP53 or RAS mutations, and returned to fight blood cancers like AML, MDS, or multiple myeloma.
Bethesda, MarylandAges 18–120 - NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years - NCT06930352RecruitingPhase 2
Ziftomenib for newly diagnosed AML with NPM1 or KMT2A changes
This trial tests an oral drug called ziftomenib for people with a type of acute myeloid leukemia (AML) that has certain genetic changes (NPM1 mutation or KMT2A rearrangement) and who are not able to receive standard chemotherapy. The goal is to see if ziftomenib can help control the leukemia.
Columbus, OhioAges 18 years+ - NCT06917911RecruitingPhase 2
Testing two drug additions to standard chemotherapy for a type of acute myeloid leukemia
This trial tests whether adding venetoclax or gemtuzumab ozogamicin to the usual chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) respond better. It may improve chances of remission.
Pembroke Pines, FloridaAges 18–59 - NCT07306832RecruitingPhase 1
Study of IV Pivekimab Sunirine for Children with Relapsed AML
This study tests an experimental IV drug called pivekimab sunirine for children whose acute myeloid leukemia (AML) has returned or not responded to previous treatments. The drug targets a specific marker on leukemia cells (CD123) to try to kill them.
Palo Alto, CaliforniaAges 6 months–17 years - NCT05554406RecruitingPhase 2
New drug therapy for high-risk AML
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
Birmingham, AlabamaAges 18–59 - NCT07581002RecruitingPhase 2/Phase 3
New AML Treatment With Three Drug Combination Study
This study tests a new three-drug combination (pivekimab sunirine, venetoclax, and azacitidine) for newly diagnosed acute myeloid leukemia in patients who cannot tolerate intensive chemotherapy. The goal is to see if this combination is safe and effective at controlling the disease.
Duarte, CaliforniaAges 18 years+ - NCT07439211RecruitingPhase 1
Testing a new drug combo for acute myeloid leukemia
This trial tests a new drug, eganelisib, combined with azacitidine and venetoclax for patients with acute myeloid leukemia (AML). It's for people whose AML has come back or hasn't responded to treatment, or for those with a high-risk type who haven't been treated yet.
Boston, MassachusettsAges 18–90 - NCT06834282RecruitingPhase 1
A study of CER-1236 for certain blood cancers
This trial tests an experimental cell therapy called CER-1236 for people with acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis. It aims to see if it can help treat these cancers.
Sacramento, CaliforniaAges 18–85 - NCT05587049Recruiting
Testing an oral medicine plus azacitidine to improve AML disease
This study looks at how a standard AML treatment plan affects a person’s disease status over time. It focuses on newly diagnosed adults who cannot safely get intensive chemotherapy, using oral venetoclax plus azacitidine.
Medellín, AntioquiaAges 18 years+ - NCT07437950RecruitingPhase 2
Comparing treatment lengths for venetoclax in older adults with newly diagnosed acute myeloid leukemia
This study tests whether a shorter or longer course of the drug venetoclax works better for older adults with a type of blood cancer called acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The goal is to find the best treatment duration to control the cancer while reducing side effects.
Bloomington, IllinoisAges 60 years+ - NCT05702645Recruiting
Down syndrome long-term study after leukemia treatment
This study follows children and young adults with Down syndrome who have survived acute leukemia (ALL or AML) to learn about their longer-term health after treatment ends. It may help families and doctors understand what health problems to watch for and how to provide better follow-up care.
Birmingham, AlabamaAges 6–39 - NCT07022678RecruitingPhase 3
Xylitol dental wipes to reduce infection risk in childhood leukemia
This trial tests whether using xylitol dental wipes can lower the risk of bloodstream infections in children with acute myeloid leukemia (AML) who are receiving chemotherapy. If you or your child have AML and will have at least two cycles of chemo that include cytarabine, this study may help reduce infection risk.
Birmingham, AlabamaAges 1–25 - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Birmingham, AlabamaAges Up to 22 years - NCT07784309Enrolling by invitationPhase 1
Cell therapy for CD7-positive blood cancer
This study tests a new cell therapy for people with certain types of blood cancer that have returned or not responded to standard treatments. The therapy uses immune cells modified to target a marker called CD7 on cancer cells. It may help reduce or eliminate the cancer.
TianjinAges 3–70 - NCT06672146RecruitingPhase 2
New treatments for AML with an IDH2 mutation
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Tucson, ArizonaAges 18 years+ - NCT06158828RecruitingPhase 1/Phase 2
Natural Killer Cells After Half-Matched Stem Cell Transplant for High-Risk AML
This study tests a new way to prevent leukemia from returning after a half-matched stem cell transplant. It uses specially activated natural killer cells to attack remaining cancer cells. This may help people with high-risk or relapsed AML who have few other options.
St Louis, MissouriAges 18 years+ - NCT07783100RecruitingPhase 2
Combination treatment for relapsed or refractory acute myeloid leukemia
This study tests a combination of three drugs (venetoclax, chidamide, and chiglitazar) for people with acute myeloid leukemia (AML) that has not responded to standard treatment or has returned. The goal is to see if this combination can help control the leukemia and is safe.
Xiamen, FujianAges 18 years+ - NCT05183035RecruitingPhase 3
Testing venetoclax for children with relapsed AML
This study tests a drug called venetoclax in children and young adults whose acute myeloid leukemia (AML) has returned after treatment. The drug may help block cancer cell growth. The study also looks at safety and how well the drug works when given alone or with other treatments.
Phoenix, ArizonaAges 4 weeks–21 years - NCT05263284RecruitingPhase 1
Study of 8-chloroadenosine plus venetoclax for relapsed or refractory AML
This trial tests a combination of two drugs, 8-chloroadenosine and venetoclax, for people with acute myeloid leukemia (AML) that has come back or not responded to prior treatments. The goal is to see if this combination can help control the leukemia.
Duarte, CaliforniaAges 18 years+ - NCT07514936RecruitingPhase 3
Venetoclax-Azacitidine With Chidamide and CAG for Older AML Patients
This trial tests a combination of four drugs (venetoclax, azacitidine, chidamide, and CAG chemotherapy) to treat newly diagnosed acute myeloid leukemia (AML—a blood cancer) in adults aged 60–75. The goal is to see if this combination helps patients live longer and feel better.
Beijing, None SelectedAges 60–75 - NCT07582172RecruitingPhase 2
Stem Cell Transplant for Hard-to-Treat Blood Cancers in Older Adults
This trial tests a new combination of radiation and chemotherapy to prepare your body for a stem cell transplant from a matched donor. It's designed for older patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that hasn't responded well to standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT03661307RecruitingPhase 1/Phase 2
Quizartinib, decitabine, and venetoclax for AML or high-risk MDS
This early-phase trial studies a 3-drug combination to treat certain types of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) in adults. It may help by targeting cancer cells using different medicines, especially for people who may not be able to get intensive chemotherapy.
Houston, TexasAges 18 years+ - NCT06001788RecruitingPhase 1
Ziftomenib for relapsed or refractory acute myeloid leukemia
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
Gilbert, ArizonaAges 18 years+
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Leukemia, Myeloid, Acute trials by city
Studies with a site in or near these metro areas.
Leukemia, Myeloid, Acute trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for leukemia, myeloid, acute?
- Yes. Clin2 currently lists 619 recruiting leukemia, myeloid, acute studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia, myeloid, acute trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia, myeloid, acute trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.